Best practice in diagnostic immunohistochemistry: Prostate carcinoma and its mimics in needle core biopsies

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 9, 2008, Pages 1388-1396

  Paner, Gladell P ^a,b   Luthringer, Daniel J ^a   Amin, Mahul B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; PROTEIN P63;

ACINAR CELL; BASAL CELL; CELL PROLIFERATION; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NEEDLE BIOPSY; PROSTATE CARCINOMA; REVIEW;

BIOPSY, NEEDLE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 51349103515     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Srigley JR. Benign mimickers of prostatic adenocarcinoma. Mod Pathol. 2004;17:328-348.
2. Herawi M, Parwani AV, Irie J, Epstein JI. Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion. Am J Surg Pathol. 2005;29:874-880.
3. Amin M, Beach R, Gown AM, et al. Use of a novel immunohistochemical (IHC) panel (P504S, p63 and 34BE12) in the diagnosis of post-radiation therapy (PRT) prostate cancer (PCa). Mod Pathol. 2003;16:139A.
4. Bates AW, Baithun SI. Secondary solid neoplasms of the prostate: a clinicopathological series of 51 cases. Virchows Arch. 2002;440:392-396.
5. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31:1246-1255.
6. Osunkoya AO, Netto GJ, Epstein JI. Colorectal adenocarcinoma involving the prostate: report of 9 cases. Hum Pathol. 2007;38:1836-1841.
7. Green R, Epstein JI. Use of intervening unstained slides for immunohistochemical stains for high molecular weight cytokeratin on prostate needle biopsies. Am J Surg Pathol. 1999;23:567-570.
8. Wojno KJ, Epstein JI. The utility of basal cell-specific anti-cytokeratin antibody (34βE12) in the diagnosis of prostate cancer: a review of 228 cases. Am J Surg Pathol. 1995;19:251-260.
9. Abrahams NA, Ormsby AH, Brainard J. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies. Histopathology. 2002;41:35-41.
10. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gärtner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003;443:122-132.
11. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol. 2002;15:1302-1308.
12. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell-specific markers, 34βE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol. 2002;26:1161-1168.
13. Shah RB, Kunju LP, Shen R, LeBlanc M, Zhou M, Rubin MA. Usefulness of basal cell cocktail (34βE12 + p63) in the diagnosis of atypical prostate glandular proliferations. Am J Clin Pathol. 2004;122:517-523.
14. Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol. 2005;22:88-104.
15. Amin MB, Tamboli P, Varma M, Srigley JR. Postatrophic hyperplasia of the prostate gland: a detailed analysis of its morphology in needle biopsy specimens. Am J Surg Pathol. 1999;23:925-931.
16. Jiang Z, Woda BA, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001;25:1397-1404.
17. Beach R, Gown AM, De Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26:1588-1596.
18. Jiang Z, Wu CL, Woda BA, et al. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol. 2002;26:1169-1174.
19. Jiang Z, Woda BA. Diagnostic utility of α-methylacyl CoA racemase (P504S) on prostate needle biopsy. Adv Anat Pathol. 2004;11:316-321.
20. Kunju LP, Chinnaiyan AM, Shah RB. Comparison of monoclonal antibody (P504S) and polyclonal antibody to α-methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer. Histopathology. 2005;47:587-596.
21. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology. 2005;47:1-16.
22. Sung MT, Jiang Z, Montironi R, Maclennan GT, Mazzucchelli R, Cheng L. α-Methylacyl-CoA racemase (P504S)/34βE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy. Hum Pathol. 2007;38:332-341.
23. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. α-Methylacyl- CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol. 2002;26:926-931.
24. Nassar A, Amin MB, Sexton DG, Cohen C. Utility of α-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer. Appl Immunohistochem Mol Morphol. 2005;13:252-255.
25. Hameed O, Sublett J, Humphrey PA. Immunohistochemical stains for p63 and α-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol. 2005;29:579-587.
26. Molinié V, Fromont G, Sibony M, et al. Diagnostic utility of a p63/α-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod Pathol. 2004;17:1180-1190.
27. Bazinet M, Zheng W, Bégin LR, Aprikian AG, Karakiewicz PI, Elhilali MM. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology. 1997;49:721-725.
28. Varma M, Morgan M, Jasani B, Tamboli P, Amin MB. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: implications for diagnostic prostatic pathology. Am J Clin Pathol. 2002;118:202-207.
29. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256-2261.
30. Allan CH, Epstein JI. Nephrogenic adenoma of the prostatic urethra: a mimicker of prostate adenocarcinoma. Am J Surg Pathol. 2001;25:802-808.
31. Bostwick DG, Meiers I. Atypical small acinar proliferation in the prostate: clinical significance in 2006. Arch Pathol Lab Med. 2006;130:952-957.
32. Iczkowski KA. Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains. Arch Pathol Lab Med. 2006;130:835-843.
33. Jiang Z, Li C, Fischer A, Dresser K, Woda BA. Using an AMACR (P504S)/ 34βE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol. 2005;123:231-236.
34. Cohen RJ, Wheeler TM, Bonkhoff H, Rubin MA. A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma. Arch Pathol Lab Med. 2007;131:1103-1109.
35. Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Mod Pathol. 2006;19:1528-1535.
36. Herawi M, Epstein JI. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 crib-riform and noncribriform acinar adenocarcinomas of the prostate. Am J Surg Pathol. 2007;31:889-894.
37. Przybycin CG, Kunju LP, Wu AJ, Shah RB. Partial atrophy in prostate needle biopsies: a detailed analysis of its morphology, immunophenotype, and cellular kinetics. Am J Surg Pathol. 2008;32:58-64.
38. Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of α-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol. 2003;27:772-778.
39. Hameed O, Humphrey PA. Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia. Mod Pathol. 2006;19:899-906.
40. McKenney JK, Amin MB. The role of immunohistochemistry in the diagnosis of urinary bladder neoplasms. Semin Diagn Pathol. 2005;22:69-87.
41. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol. 2003;27:1-10.
42. Genega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol. 2000;13:1186-1191.
43. Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol. 2008;32:461-467.
44. Saboorian MH, Huffman H, Ashfaq R, Ayala AG, Ro JY. Distinguishing Cowper's glands from neoplastic and pseudoneoplastic lesions of prostate: immunohistochemical and ultrastructural studies. Am J Surg Pathol. 1997;21:1069-1074.
45. Bostwick DG, Qian J, Ma J, Muir TE. Mesonephric remnants of the prostate: incidence and histologic spectrum. Mod Pathol. 2003;16:630-635.
46. Malpica A, Ro JY, Troncoso P, Ordoñez NG, Amin MB, Ayala AG. Nephrogenic adenoma of the prostatic urethra involving the prostate gland: a clinicopathologic and immunohistochemical study of eight cases. Hum Pathol. 1994; 25:390-395.
47. Skinnider BF, Oliva E, Young RH, Amin MB. Expression of α-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma. Am J Surg Pathol. 2004;28:701-705.